What makes neoantigen vaccines superior to shared antigen vaccines?

Question

Accepted Answer

Neoantigen Vaccines Represent a Superior Approach Due to Their Personalised Nature

Neoantigen vaccines are considered superior to shared antigen vaccines because they are manufactured based on the unique genetic mutations of an individual patient's tumour. This personalised strategy involves sequencing a patient's tumour DNA and employing algorithms to predict specific mutant peptides that will effectively bind to their unique human leukocyte antigen (HLA) molecules. This process results in a truly individualised vaccine, a significant advancement over earlier approaches that relied on shared antigens.
Personalised Manufacturing Drives Clinical Advancement

The clinical inflection point for cancer vaccines has been significantly influenced by two parallel advancements: neoantigen discovery and personalised manufacturing capabilities. The established consensus within the field now clearly indicates a shift away from shared antigens towards private neoantigens. This means that instead of targeting antigens common to many patients, the focus is on identifying and utilising antigens that are specific to each individual's cancer.
Delivery Vehicle and Danger Signals are Critical

The effectiveness of neoantigen vaccines is not solely determined by the antigen itself, but critically by the delivery vehicle and the danger signal it conveys. A neoantigen peptide, when administered alone, may be disregarded by the immune system. However, when encapsulated within a lipid nanoparticle (LNP) that also contains an innate agonist, the peptide can trigger a potent immune response. Research indicates that the location and method of antigen delivery are more crucial than the antigen itself, with LNPs that direct to lymph nodes and are taken up by resident dendritic cells now considered the gold standard.
Early Intervention in Less Immunosuppressive Environments Yields Better Outcomes

Clinical trial data suggests that vaccines are less effective in patients with bulky, end-stage disease, largely because the tumour microenvironment actively suppresses T cells. However, promising results are emerging in earlier settings, such as post-surgery (adjuvant) or pre-surgery (neoadjuvant) phases, when the disease is not macroscopically immunosuppressive. In these scenarios, where micrometastatic disease is present but the tumour mass has not yet established a significant immunosuppressive stronghold, pathologic complete responses have been observed, indicating a potential paradigm shift to vaccinate before surgical intervention.

Reading history

Hide →

This history is cleared when the page is closed.

What makes neoantigen vaccines superior to shared antigen vaccines?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

2

0

0

Share with friends